Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid‐cycling disease course: a randomized, double‐blind, placebo‐controlled study

Quetiapine monotherapy (600 or 300 mg/day) is clinically effective and well tolerated in the short-term treatment of depressive episodes in patients with bipolar I or II disorder who have a rapid-cycling disease course.